48-mer synthetic peptide analogue of the hepatitis B virus "a" determinant induces an anti-HBs antibody response after a single injection

An extended (48 amino acid) synthetic peptide analogue of the hepatitus B virus (HBV) S protein (HBsAg) ‘a’ determinant has been produced by using 9‐fluorenylmethoxycarbonyl (fmoc) chemistry and a low substitution polystyrene resin as the solid phase support. This peptide (S121/48) elicited a sustai...

Full description

Saved in:
Bibliographic Details
Published inJournal of medical virology Vol. 62; no. 2; pp. 159 - 166
Main Authors Moynihan, Jennifer S., D'Mello, Felicity I.M., Howard, Colin R.
Format Journal Article
LanguageEnglish
Published New York John Wiley & Sons, Inc 01.10.2000
Wiley-Liss
Subjects
Online AccessGet full text
ISSN0146-6615
1096-9071
DOI10.1002/1096-9071(200010)62:2<159::AID-JMV6>3.0.CO;2-X

Cover

More Information
Summary:An extended (48 amino acid) synthetic peptide analogue of the hepatitus B virus (HBV) S protein (HBsAg) ‘a’ determinant has been produced by using 9‐fluorenylmethoxycarbonyl (fmoc) chemistry and a low substitution polystyrene resin as the solid phase support. This peptide (S121/48) elicited a sustained anti‐peptide antibody response in BALB/c (H‐2d) mice when immunised with Freund's complete adjuvant (FCA). Cross‐reactive, anti‐HBs antibodies were induced, directed against a significant proportion of the conformationally restrained epitope repertoire on the native HBsAg particles. Similar responses were obtained by injection of guinea pigs, a species known both to be exquisitely sensitive to HBsAg and to produce a wide range of B cell responses to HBsAg antigens. Taken together, these data show for the first time, that a synthetic peptide mimicking conformational epitopes can be produced by chemical synthesis and can be used to induce significant titres of anti‐HBs antibodies after a single injection. This immunogen has considerable potential for incorporation into novel delivery systems, e.g., microspheres, thus offering the potential of a controlled release, single dose hepatitis B vaccine. J. Med. Virol. 62:159–166, 2000. © 2000 Wiley‐Liss, Inc.
Bibliography:istex:38CD5B5FE63E5A8784FAF1D33954BFCA6F99FC26
ark:/67375/WNG-RV1ZJWKW-H
ArticleID:JMV6
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0146-6615
1096-9071
DOI:10.1002/1096-9071(200010)62:2<159::AID-JMV6>3.0.CO;2-X